Site MapКарта сайта

We are very glad to welcom you
on Web-server of LLC “Pharmtechnology”!



Pharmtechnology LLC has operated in pharmaceutical market since 1991.

In 1994 was bought the unfinished and unused construction project (bookselling base) with the adjacent territory in the Octiabrskii district in Minsk.

In 1996 Design-Construction Medicinal-Biotechnological Institute (MedBioP) designed a project of pharmaceutical production.

In 1998 the first stage of medicines production was put into operation.

It should be noted that in order to move forward it is necessary to invest significant means in new technologies and personnel training. Nearly all profit of Pharmtechnology LLC for more than 20 years of its existence was reinvested in its development.

In October 2012 Pharmtechnology became the first and as of today remains an exclusive domestic enterprise of pharma industry that received an international GMP PIC/S correspondence certificate. It is worth noting that the GMP PIC /S Certificate was received after the first inspection.

Currently PIC/S includes more than 43 members (among them are Switzerland, Germany, France, Italy, Canada, USA, Australia, Japan, South Korea, Brazil, etc.).
The inspection results are mutually recognized by all PIC/S member-countries.

Inspection of Pharmtechnology by the PIC/S international inspectorate organization (Pharmaceutical Inspection Cooperation Scheme) in March 2014 has confirmed the status of conformity with GMP PIC/S international standards of quality assurance and control, which was received in 2012.

At the moment our stock-list includes more than 150 medicines of different pharmacotherapeutic groups and dosage forms (tablets, ointments, gels, syrups, nasal solutions and sprays). Most of them have been included into the manufacturing plan as a part of the national import substitution program.

Pharmtechnology LLC owns 43.3% of the national pharmaceutical market of generic drugs ( i.e. medical drugs with the same API and in the same dosage form) in monetary value and 46.3% in material value. Our company has been increasing the manufacturing capacity recently in order to supply our citizens with the medical drugs of European quality.